Assembly Biosciences Inc - Asset Resilience Ratio

Latest as of June 2026: 87.08%

Assembly Biosciences Inc (ASMB) has an Asset Resilience Ratio of 87.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ASMB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$288.07 Million
Cash + Short-term Investments

Total Assets

$330.83 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Assembly Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Assembly Biosciences Inc balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Assembly Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Assembly Biosciences Inc (ASMB) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $288.07 Million 87.08%
Total Liquid Assets $288.07 Million 87.08%

Asset Resilience Insights

  • Very High Liquidity: Assembly Biosciences Inc maintains exceptional liquid asset reserves at 87.08% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Assembly Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Assembly Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Assembly Biosciences Inc (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Assembly Biosciences Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 73.63% $189.66 Million $257.59 Million +11.75pp
2024-12-31 61.87% $73.73 Million $119.17 Million -18.82pp
2023-12-31 80.69% $110.41 Million $136.82 Million +42.19pp
2022-12-31 38.50% $39.19 Million $101.79 Million -14.36pp
2021-12-31 52.86% $101.00 Million $191.06 Million -2.55pp
2020-12-31 55.42% $156.97 Million $283.25 Million -9.92pp
2019-12-31 65.34% $227.31 Million $347.89 Million -0.55pp
2018-12-31 65.89% $176.61 Million $268.05 Million +43.49pp
2017-12-31 22.39% $37.91 Million $169.30 Million -2.46pp
2016-12-31 24.86% $24.39 Million $98.12 Million -5.47pp
2015-12-31 30.32% $40.56 Million $133.74 Million --
2014-12-31 0.00% $0.00 $71.23 Million --
2013-12-31 0.00% $0.00 $27.13 Million --
2012-12-31 0.00% $0.00 $20.56 Million --
2011-12-31 0.00% $0.00 $37.05 Million --
pp = percentage points

About Assembly Biosciences Inc

NASDAQ:ASMB USA Biotechnology
Market Cap
$518.79 Million
Market Cap Rank
#12136 Global
#3044 in USA
Share Price
$25.48
Change (1 day)
-12.02%
52-Week Range
$22.26 - $38.50
All Time High
$769.92
About

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more